Product Description
Mechanisms of Action: VEGFR2 Inhibitor,AhR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colorectal Cancer
Phase 2: Uterine Cancer|Sarcoma|Gastrointestinal Stromal Tumors|Plasmacytoma|Cervical Cancer|Mesothelioma|Prostate Cancer|Multiple Myeloma|Renal Cell Carcinoma|Colorectal Cancer|Adenocarcinoma|Melanoma|Glioma|Sarcoma, Kaposi|Head and Neck Cancer|Squamous Cell Carcinoma|Skin Cancer|Kidney Cancer|Brain Stem Cancer|HIV Infections|Astrocytoma|Acute Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Acute Monocytic Leukemia
Phase 1: Vascular Cancer|Sarcoma, Kaposi|Head and Neck Cancer|Oncology Solid Tumor Unspecified|Fallopian Tube Cancer|Peritoneal Cancer|Prostate Cancer|Inflammatory Breast Cancer|Ovarian Cancer|Brain Stem Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SUGEN-SU5416.031 | P3 |
Completed |
Colorectal Cancer |
2007-09-01 |
|
| NCI-2012-02351 | P2 |
Completed |
Mesothelioma |
2007-02-01 |
|
| U01CA062505 | P2 |
Completed |
Renal Cell Carcinoma|Kidney Cancer |
2007-02-01 |
|
| NCI-2012-02345 | P2 |
Terminated |
Colorectal Cancer |
2007-02-01 |